2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Carcinoma
2
Sezary Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Rectal Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, Non-Hodgkin
1
Liposarcoma, Myxoid
1
Leukemia, Myeloid
1
Hodgkin Disease
1
HIV Infections
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Vincristine
2
Temozolomide
2
Oncolytic Virotherapy
2
vorasidenib
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
lutetium Lu 177 dotatate
1
interferon gamma-1b
1
copper dotatate CU-64
1
cixutumumab
1
Vorinostat
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lutetium-177
1
Lutetium
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled